Signal amplifcation by reversible exchange for COVID‐19 antiviral drug candidates
| dc.creator | Jeong, Hye Jin | |
| dc.creator | Min, Sein | |
| dc.creator | Chae, Heelim | |
| dc.creator | Kim, Sarah | |
| dc.creator | Lee, Gunwoo | |
| dc.creator | Namgoong, Sung Keon | |
| dc.creator | Jeong, Keunhong | |
| dc.date.accessioned | 2020-09-17T20:12:24Z | |
| dc.date.available | 2020-09-17T20:12:24Z | |
| dc.date.created | 2020 | |
| dc.description.abstract | Several drug candidates have been proposed and tested as the latest clinical treatment for coronavirus pneumonia (COVID-19). Chloroquine, hydroxychloroquine, ritonavir/lopinavir, and favipiravir are under trials for the treatment of this disease. The hyperpolarization technique has the ability to further provide a better understanding of the roles of these drugs at the molecular scale and in diferent applications in the feld of nuclear magnetic resonance/magnetic resonance imaging. This technique may provide new opportunities in diagnosis and research of COVID-19. Signal amplifcation by reversible exchange-based hyperpolarization studies on large-sized drug candidates were carried out. We observed hyperpolarized proton signals from whole structures, due to the unprecedented long-distance polarization transfer by para-hydrogen. We also found that the optimal magnetic feld for the maximum polarization transfer yield was dependent on the molecular structure. We can expect further research on the hyperpolarization of other important large molecules, isotope labeling, as well as polarization transfer on nuclei with a long spin relaxation time. A clinical perspective of these features on drug molecules can broaden the application of hyperpolarization techniques for therapeutic studies | spa |
| dc.format.extent | 13 Páginas | spa |
| dc.format.mimetype | text/html | spa |
| dc.identifier.doi | https://doi.org/10.1038/s41598-020-71282-6 | spa |
| dc.identifier.issn | 2045 2322 | spa |
| dc.identifier.other | https://doi.org/10.1038/s41598-020-71282-6 | spa |
| dc.identifier.uri | https://hdl.handle.net/20.500.12010/13384 | |
| dc.language.iso | eng | spa |
| dc.publisher | Scientific reports | spa |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | spa |
| dc.rights.local | Abierto (Texto Completo) | spa |
| dc.source | reponame:Expeditio Repositorio Institucional UJTL | spa |
| dc.source | instname:Universidad de Bogotá Jorge Tadeo Lozano | spa |
| dc.subject | COVID‑19 | spa |
| dc.subject | Antiviral drugs | spa |
| dc.subject.lemb | Síndrome respiratorio agudo grave | spa |
| dc.subject.lemb | COVID-19 | spa |
| dc.subject.lemb | SARS-CoV-2 | spa |
| dc.subject.lemb | Coronavirus | spa |
| dc.title | Signal amplifcation by reversible exchange for COVID‐19 antiviral drug candidates | spa |
| dc.type.coar | http://purl.org/coar/resource_type/c_2df8fbb1 | spa |
| dc.type.hasversion | info:eu-repo/semantics/acceptedVersion | spa |
| dc.type.local | Artículo | spa |
Archivos
Bloque original
1 - 1 de 1
Cargando...
- Nombre:
- s41598-020-71282-6.pdf
- Tamaño:
- 3.59 MB
- Formato:
- Adobe Portable Document Format
- Descripción:
- Ver artículo
Bloque de licencias
1 - 1 de 1
Cargando...
- Nombre:
- license.txt
- Tamaño:
- 2.87 KB
- Formato:
- Item-specific license agreed upon to submission
- Descripción:
